A new candidate in the treatment of Covid:

Medical: Professor Yaakov Nahmias' team at the Hebrew University of Jerusalem .. identified the lipid-lowering drug TriCor (fenofibrate) as an effective antiviral last year, showing it both reduced lung cell damage and blocked virus replication in the laboratory. These results have since been confirmed by several international research teams. An observational study carried out in multiple clinical centers in Israel was reported last October to support the original findings.

15 severe-hospitalized COVID-19 patients with pneumonia requiring oxygen support were treated. The patients were given 145 mg/day of TriCor (fenofibrate) for 10 days and continuously monitored for disease progression and outcomes.

Nahmias: The results were astounding. Progressive inflammation markers, that are the hallmark of deteriorative COVID-19, dropped within 48 hours of treatment. Moreover, 14 of the 15 severe patients didn't require oxygen support within a week of treatment, while historical records show that the vast majority severe patients treated with the standard of care require lengthy respiratory support.

Prof. Shlomo Maayan, Head of Infectious Disease Unit at Barzilai: All patients were discharged within less than a week after the treatment began and were discharged to complete the 10-day treatment at home, with no drug-related adverse events reported. Further, fewer patients reported COVID-19 side effects during their 4-week follow-up appointment.

Medical: TriCor (fenofibrate) was approved by the FDA in 1975 for long-term use and has a strong safety record.

Another example of an existing drug with a track record of safe usage that works against Covid - but appears to have been ignored in 'the great vaccine quest'. Guess it's no coincidence that it has come to light in Israel where they have one of the the highest rates of vaccination in the world but are facing a post-vac wave.

Found it on @BillyBostickson - but you have to wonder why this isn't headline news around the world.